ZA974030B - Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids. - Google Patents

Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids.

Info

Publication number: ZA974030B
Authority: ZA; South Africa
Prior art keywords: inhibition; matrix metalloproteases; substituted biaryl; oxobutyric acids; oxobutyric
Prior art date: 1996-05-15

Application number

ZA9704030A

Other languages

English (en)

Inventor

Michael C Van Zandt

David R Brittelli

Brian R Dixon

Original Assignee

Bayer Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-15

Filing date

1997-05-09

Publication date

1998-02-19

1997-05-09 Application filed by Bayer Ag filed Critical Bayer Ag

1998-02-19 Publication of ZA974030B publication Critical patent/ZA974030B/xx

Links

102000005741 Metalloproteases Human genes 0.000 title 1
108010006035 Metalloproteases Proteins 0.000 title 1
239000002253 acid Substances 0.000 title 1
150000007513 acids Chemical class 0.000 title 1
125000005841 biaryl group Chemical group 0.000 title 1
230000005764 inhibitory process Effects 0.000 title 1
239000011159 matrix material Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/04—1,2,3-Triazines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Hematology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Neurology (AREA)
Vascular Medicine (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Thiazole And Isothizaole Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Peptides Or Proteins (AREA)

ZA9704030A 1996-05-15 1997-05-09 Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids. ZA974030B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US64849396A	1996-05-15	1996-05-15

Publications (1)

Publication Number	Publication Date
ZA974030B true ZA974030B (en)	1998-02-19

Family

ID=24601014

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA9704030A ZA974030B (en)	1996-05-15	1997-05-09	Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids.

Country Status (24)

Country	Link
EP (1)	EP0923530B1 (id)
JP (1)	JP3354942B2 (id)
CN (1)	CN1100748C (id)
AR (1)	AR007098A1 (id)
AT (1)	ATE275123T1 (id)
AU (1)	AU714207B2 (id)
BR (1)	BR9709086A (id)
CA (1)	CA2254731C (id)
CO (1)	CO5011061A1 (id)
DE (1)	DE69730508T2 (id)
DK (1)	DK0923530T3 (id)
ES (1)	ES2227696T3 (id)
HR (1)	HRP970244B1 (id)
ID (1)	ID17291A (id)
MY (1)	MY132463A (id)
PA (1)	PA8429701A1 (id)
PE (1)	PE66898A1 (id)
PT (1)	PT923530E (id)
SV (1)	SV1997000036A (id)
TN (1)	TNSN97083A1 (id)
TW (1)	TW539672B (id)
WO (1)	WO1997043239A1 (id)
YU (1)	YU18597A (id)
ZA (1)	ZA974030B (id)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5925637A (en) *	1997-05-15	1999-07-20	Bayer Corporation	Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids
US6288063B1 (en)	1998-05-27	2001-09-11	Bayer Corporation	Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
EP1031349A1 (en) *	1999-02-25	2000-08-30	Bayer Aktiengesellschaft	Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
GB9922710D0 (en) *	1999-09-24	1999-11-24	Bayer Ag	Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis
PA8539401A1 (es) *	2001-02-14	2002-10-28	Warner Lambert Co	Quinazolinas como inhibidores de mmp-13
JP2004359546A (ja) *	2001-03-15	2004-12-24	Ono Pharmaceut Co Ltd	ヒドロキサム酸誘導体、それらの非毒性塩およびそれらのプロドラッグ体を有効成分として含有する、固形癌の予防および／または治療剤
JPWO2002074298A1 (ja) *	2001-03-21	2004-07-08	小野薬品工業株式会社	Ｉｌ−６産生阻害剤
KR101405823B1 (ko) *	2007-12-24	2014-06-12	주식회사 케이티앤지생명과학	녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) *	2007-12-28	2009-07-02	주식회사 머젠스	신장질환의 치료 및 예방을 위한 약제 조성물
US9643922B2 (en)	2008-08-18	2017-05-09	Yale University	MIF modulators
US9540322B2 (en)	2008-08-18	2017-01-10	Yale University	MIF modulators
US20120040974A1 (en) *	2008-08-18	2012-02-16	Yale University	Mif modulators
US20170022171A1 (en)	2014-04-03	2017-01-26	Bayer Pharma Aktiengesellschaft	2,5-disubstituted cyclopentanecarboxylic acids and their use
US20170119776A1 (en)	2014-04-03	2017-05-04	Bayer Pharma Aktiengesellschaft	Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
CA2944614A1 (en)	2014-04-03	2015-10-08	Bayer Pharma Aktiengesellschaft	2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases
CN113979992B (zh) *	2021-11-19	2022-06-24	西安欧得光电材料有限公司	一种3-取代二苯并噻吩及其合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0905126B1 (en) *	1994-01-22	2002-12-04	British Biotech Pharmaceuticals Limited	Metalloproteinase inhibitors
NZ323329A (en)	1995-12-22	1999-02-25	Warner Lambert Co	4-phenyl-piperidin-1-yl butyric acid derivatives and medicaments
HRP970242A2 (en)	1996-05-15	1998-04-30	Bayer Ag	Inhibition of matrix metalloproteases by 2-(omega-aroylalkyl)-4-biaryl-oxobutric acids

1997
- 1997-05-09 CO CO97025174A patent/CO5011061A1/es unknown
- 1997-05-09 ZA ZA9704030A patent/ZA974030B/xx unknown
- 1997-05-09 TN TNTNSN97083A patent/TNSN97083A1/fr unknown
- 1997-05-09 MY MYPI97002043A patent/MY132463A/en unknown
- 1997-05-09 HR HR970244A patent/HRP970244B1/xx not_active IP Right Cessation
- 1997-05-12 TW TW086106285A patent/TW539672B/zh not_active IP Right Cessation
- 1997-05-12 WO PCT/US1997/007976 patent/WO1997043239A1/en not_active Ceased
- 1997-05-12 CN CN97196454A patent/CN1100748C/zh not_active Expired - Fee Related
- 1997-05-12 SV SV1997000036A patent/SV1997000036A/es not_active Application Discontinuation
- 1997-05-12 PA PA19978429701A patent/PA8429701A1/es unknown
- 1997-05-12 ES ES97926455T patent/ES2227696T3/es not_active Expired - Lifetime
- 1997-05-12 BR BR9709086A patent/BR9709086A/pt not_active Application Discontinuation
- 1997-05-12 AR ARP970101978A patent/AR007098A1/es unknown
- 1997-05-12 PT PT97926455T patent/PT923530E/pt unknown
- 1997-05-12 DK DK97926455T patent/DK0923530T3/da active
- 1997-05-12 DE DE69730508T patent/DE69730508T2/de not_active Expired - Fee Related
- 1997-05-12 YU YU18597A patent/YU18597A/sh unknown
- 1997-05-12 AU AU31220/97A patent/AU714207B2/en not_active Ceased
- 1997-05-12 JP JP54100397A patent/JP3354942B2/ja not_active Expired - Fee Related
- 1997-05-12 EP EP97926455A patent/EP0923530B1/en not_active Expired - Lifetime
- 1997-05-12 AT AT97926455T patent/ATE275123T1/de not_active IP Right Cessation
- 1997-05-12 PE PE1997000365A patent/PE66898A1/es not_active Application Discontinuation
- 1997-05-12 CA CA002254731A patent/CA2254731C/en not_active Expired - Fee Related
- 1997-05-14 ID IDP971611A patent/ID17291A/id unknown

Also Published As

Publication number	Publication date
ATE275123T1 (de)	2004-09-15
BR9709086A (pt)	1999-08-03
JP3354942B2 (ja)	2002-12-09
DK0923530T3 (da)	2005-01-03
DE69730508T2 (de)	2005-09-29
MY132463A (en)	2007-10-31
AU3122097A (en)	1997-12-05
ES2227696T3 (es)	2005-04-01
HRP970244B1 (en)	2005-06-30
PT923530E (pt)	2004-12-31
DE69730508D1 (de)	2004-10-07
AR007098A1 (es)	1999-10-13
EP0923530B1 (en)	2004-09-01
CN1225621A (zh)	1999-08-11
EP0923530A1 (en)	1999-06-23
AU714207B2 (en)	1999-12-23
TNSN97083A1 (fr)	2005-03-15
SV1997000036A (es)	1998-07-20
HK1021897A1 (en)	2000-07-14
WO1997043239A1 (en)	1997-11-20
CA2254731C (en)	2004-07-20
HRP970244A2 (en)	1998-04-30
CA2254731A1 (en)	1997-11-20
JPH11510821A (ja)	1999-09-21
PE66898A1 (es)	1998-10-22
CO5011061A1 (es)	2001-02-28
CN1100748C (zh)	2003-02-05
PA8429701A1 (es)	2000-05-24
ID17291A (id)	1997-12-18
TW539672B (en)	2003-07-01
YU18597A (sh)	2001-12-26

Publication	Publication Date	Title
ZA977700B (en)	1998-02-23	Phosphinic acid amides as matrix metalloprotease inhibitors.
GB9602877D0 (en)	1996-04-10	3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
ZA974030B (en)	1998-02-19	Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids.
TR199501472A2 (tr)	1996-07-21	Matriks metaloproteaz inhibitörler.
HU9801045D0 (en)	1998-07-28	Substituted diamino-carboxylic acids
IL128663A0 (en)	2000-01-31	1,4-heterocyclic metalloprotease inhibitors
IL128661A0 (en)	2000-01-31	1,3-diheterocyclic metalloprotease inhibitors
ZA977696B (en)	1998-02-23	Diheterocyclic metalloprotease inhibitors.
BR9612707A (pt)	1999-07-27	Composiç o detergente compreendendo uma enzima pectinesterase
ZA96850B (en)	1997-11-03	Matrix metalloprotease inhibitors.
ZA975631B (en)	1998-01-30	Matrix metalloproteinase inhibitors.
ZA979756B (en)	1999-11-01	Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors.
ZA978307B (en)	1998-03-19	3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase.
HRP970242A2 (en)	1998-04-30	Inhibition of matrix metalloproteases by 2-(omega-aroylalkyl)-4-biaryl-oxobutric acids
ZA974031B (en)	1998-02-19	Biaryl acetylenes as inhibitors of matrix metalloproteases.
ZA974033B (en)	1998-02-19	Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors.
HRP970243A2 (en)	1998-04-30	Inhibition of matrix metalloproteases by substituted phenethyl compounds
ZA974032B (en)	1998-02-19	Substituted oxobutyric acids as matrix metalloproteinases inhibitors.
ZA987896B (en)	2000-02-28	Malonic acid based matrix metalloproteinase inhibitors.
GB2315081A8 (en)	1998-02-10	Hoardings
ZA977916B (en)	1998-03-03	Method of inhibiting matrix metalloproteinases.
ZA974806B (en)	1997-12-30	Prostaglandin synthase-2 inhibitor.
ZA9810004B (en)	2000-05-02	Substituted anilides.
ZA9610604B (en)	1997-06-20	Matrix metalloprotease inhibitors
ID19267A (id)	1998-06-28	Senyawa baru yang bermanfaat sebagai inhibitor matriks metaloprotease